drugset / Trial / NCT04745559
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
Timeline
- Start
- 2021-02-18
- Primary completion
- 2025-07-31
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 targeted CAR T Cell Therapy | Cell therapy | — | — |
| Subject | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |